Schizophrenia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for schizophrenia. 601 active patents protecting 9 drugs from 7+ originators. First major cliff: 2026. Daily refresh.

9
Approved drugs
601
Active US patents
58/100
Avg vulnerability
$9.0B
Annual revenue covered

Originators in Schizophrenia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Johnson & Johnson (Janssen) 139 patents Alkermes Inc 71 patents Eli Lilly 56 patents Vanda Pharms Inc 56 patents Otsuka 46 patents Hisamitsu 18 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating schizophrenia. Each bar = one year. Y-axis scaled to peak year (102 patents).

53
26
42
27
24
28
60
29
91
30
102
31
43
32
83
33
8
34
22
35
4
36
6
38
16
39
17
40
6
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Risperdal
risperidone
 Johnson & Johnson (Janssen) 110 56 — 2026-06-26
Aristada
ARIPIPRAZOLE LAUROXIL
 Alkermes Inc 71 44 $500M 2030-06-24
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23
Fanapt
ILOPERIDONE
 Vanda Pharms Inc 56 69 — 2027-11-02
Rexulti
BREXPIPRAZOLE
 Otsuka 46 59 $1.4B 2026-10-12
Invega Sustenna
PALIPERIDONE PALMITATE
 Johnson & Johnson 29 71 $3.8B 2031-01-26
Saphris
ASENAPINE
 Hisamitsu 18 33 — 2033-07-25
Adasuve
LOXAPINE
 — 1 65 — 2026-10-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
12194035 Zyprexa method of use 81 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8431576 Aristada composition of matter 0 2030-10-26
8431576 Aristada composition of matter 0 2030-10-26
8431576 Aristada composition of matter 0 2030-10-26
8431576 Aristada composition of matter 0 2030-10-26
8431576 Aristada composition of matter 0 2030-10-26
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
RE48059 Rexulti composition of matter 17 2028-12-23

Related